GH Research FY25 Results: Strong Cash Position As GH001 Advances Toward Phase 3 [Seeking Alpha]
GH Research PLC - Ordinary Shares (GHRS)
Company Research
Source: Seeking Alpha
GHRS's investment thesis centers on replicating strong Phase 2b efficacy for GH001 in a pivotal Phase 3 trial, with rapid, durable antidepressant effects and operational simplicity. The FDA has cleared GH001 for U.S. clinical investigation, positioning GHRS for a global Phase 3 program starting in 2026 without immediate capital constraints. Valuation hinges on clinical and regulatory progress for GH001, with the stock trading at a modest premium to book and upside tied to Phase 3 replication. Trevor Williams/DigitalVision via Getty Images Thesis GH Research PLC ( GHRS reported an FY25 GAAP EPS of -$0.79. This was somewhat expected, as they're still continuing investment in clinical development. The firm also managed to end the year with a decent cash This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote th
Show less
Read more
Impact Snapshot
Event Time:
GHRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GHRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GHRS alerts
High impacting GH Research PLC - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
GHRS
News
- GH Research (GHRS) was given a new $34.00 price target by Guggenheim.MarketBeat
- GH Research (GHRS) had its price target raised by Citizens Jmp from $39.00 to $42.00. They now have a "market outperform" rating on the stock.MarketBeat
- GH Research (GHRS) had its price target raised by Needham & Company LLC from $31.00 to $32.00. They now have a "buy" rating on the stock.MarketBeat
- GH Research GAAP EPS of -$0.79 [Seeking Alpha]Seeking Alpha
- GH Research Reports Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
GHRS
Earnings
- 3/5/26 - Miss
GHRS
Sec Filings
- 3/16/26 - Form 6-K
- 3/5/26 - Form S-8
- 3/5/26 - Form 20-F
- GHRS's page on the SEC website